Abstract
The polycystic ovary syndrome (PCOS), characterized by chronic anovulation and hyperandrogenism, has many features of metabolic syndrome and can be considered a metabolic disease. Approximately 50% of patients with PCOS are overweight or obese with abdominal fat accumulation. Some metabolic alterations and abdominal fat distribution have also been reported in lean women with PCOS. The aim of this study was to evaluate the effect, if any, of obesity on metabolic features, body composition and fat distribution in patients with PCOS. Body composition and abdominal fat distribution (evaluated by DEXA), waist circumference, blood pressure, lipid profile, glucose tolerance and homeostasis model assessment index were determined in 23 lean [mean age 23±5 yr, mean body mass index (BMI) 22±2 kg/m2] and 27 overweight-obese (mean age 21±5 yr, mean BMI 32±5 kg/m2) patients with PCOS and in 20 age- and weight-matched eumenorrhoic women. Patients exhibited slight but non-significant differences in metabolic parameters, waist circumference, blood pressure and total and abdominal fat content compared with weight-matched controls. None of the lean subjects suffered from metabolic syndrome according to the National Cholesterol Education Program — Adult Treatment Panel III (NCEP-ATPIII) criteria as opposed to 10 overweightobese patients and three overweight-obese control subjects (37% and 33.3% of each subgroup, respectively). Our data do not show significant metabolic alterations in lean PCOS women. Results indicate that obesity seems to underpin the metabolic alterations exhibited by the overweightobese patients. However, since women with PCOS are at increased cardiovascular risk, further studies are needed to evaluate metabolic alterations and body composition in these patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Franks S. Polycystic ovary syndrome. N Engl J Med 1995, 333: 853–61.
Knochenauer ES, Key TJ, Kashar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998, 83: 3078–82.
Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endrocrinol Metab 1999, 84: 4006–11.
Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000, 85: 2434–8.
Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, eds. Polycystic ovary syndrome. Current Issues in Endocrinology and Metabolism, 4. Boston: Blackwell. 1992, 377–84.
Lobo RA, Carmina E. The importance of diagnosing the poly-cystic ovary syndrome. Ann Intern Med 2000, 132: 989–93.
Carmina E, Lobo RA. Polycystic ovary syndrome: arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999, 84: 1897–9.
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18: 774–800.
Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999, 20: 535–82.
Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-months trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000, 85: 139–46.
Moghetti P. Advances in the treatment of polycystic ovary syndrome. Expert Opin Investig Drugs 2001, 10: 1631–40.
Pasquali R, Gambineri A, Biscotti D, et al. Effect of longterm treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2000, 85: 2767–4.
Pasquali R, Gambineri A, Anconetani B, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of the long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999, 50: 517–27.
Gennarelli G, Holte J, Berglund L, Berne C, Massobrio M, Lithell H. Prediction models for insulin resistance in the poly-cystic ovary syndrome. Hum Reprod 2000, 15: 2098–102.
Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and β-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 2001, 86: 66–71.
Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictions of the risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84: 165–74.
Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connel JM. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 742–6.
Pasquali R, Casimirri F. The impact of obesity on hyperan-drogenism and polycystic ovary syndrome in premenopau-sal women. Clin Endocrinol (Oxf) 1993, 39: 1–16.
Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002, 26: 883–96.
Douchi T, Ijuin H, Nakamura S, Oki T, Yamamoto S, Nagata Y. Body fat distribution in women with polycystic ovary syndrome. Obstet Gynecol 1995, 86: 516–9.
Depres J P, Allard B, Tremblay A, Bouchard C. Evidence for a regional component of fatness in the association with serum lipids in men and women. Metabolism 1985, 34: 967–73.
Dunahue RP, Abott RD, Bloom E, Reed DM, Yano K. Central obesity and coronary hearth disease. Lancet 1987, 1: 821–4.
Bjorntorp P. The android woman-a risky condition. J Intern Med 1996, 239: 105–10.
Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001, 16: 1255–60.
Good C, Tulchinsky M, Mauger D, Demers LM, Legro RS. Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertil Steril 1999, 72: 21–5.
Ferriman D, Gallway JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961, 21: 1440–7.
Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries: a common finding in normal women. Lancet 1988, 1: 870–2.
Michelmore KP, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 1999, 51: 779–86.
Lakhani K, Seifalian AM, Atiomo WU, Hardiman P. Polycystic ovaries. Br J Radiol 2002, 75: 9–16.
Chang PL, Lindheim SR, Lowre C, et al. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing. J. Clin. Endocrinol. Metab. 2000, 85(3): 995–1000.
Norman RJ, Hague WM, Masters SC, Wang XJ. Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. Hum Reprod 1995, 10: 2258–61.
WHO. Measuring obesity-classification and description of anthropometric data. 1988 Copenhagen, Denmark: WHO Regional Office for Europe; Eur/ICP/NUT 125-0612v.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1999, 22 (Suppl 1): S5–S19.
Alberti KG, Zimmer P. Definition, diagnosis and classification of diabetes mellitus and its complications. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998, 15: 539–53.
Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84: 3666–72.
Rosner W. An extraordinarily inaccurate assay for free testosterone is still with us. J Clin Endocrinol Metab 2001, 86: 2903.
Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab 1998, 63: 134–41.
Matsuda M, De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22: 1462–70.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.
Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998
Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women. Diabetes 1996, 45: 633–8.
Svendsen OL, Hassager C, Bergmann I, Christiansen C. Measurement of abdominal and intra-abdominal fat in post menopausal women by dual energy X-ray absorptiometry and anthropometry: comparison with computerised tomography. Int J Obes 1993, 17: 45–51.
Jensen MD, Kanaley JA, Reed JE, Sheedy PF. Measurements of abdominal and visceral fat with computed tomography and dual-energy X-ray absorptiometry. Am J Clin Nutr 1995, 61: 274–8.
Kamel EG, McNeill G, Han TS, et al. Measurement of abdominal fat by magnetic resonance imaging, dual-energy X-ray absorptiometry and anthropometry in non-obese men and women. Int J Obes Relat Metab Disord 1999, 23: 686–92.
Kamel EG, McNeill G, Van Wijk MC. Change in intra-ab-dominal adipose tissue volume during weight loss in obese men and women: correlation between magnetic resonance imaging and anthropometric measurements. Int J Obes Relat Metab Disord 2000, 24: 607–13.
Haarbo J, Gotfredsen A, Hassager C, Christiansen C. Validation of body composition by dual energy X-ray absorptiom-etry (DEXA). Clin Physiol 1991, 11: 331–41.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP ATP-III) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285: 2486–97.
Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 1994, 41: 463–71.
Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in pre-menopausal women. Clin Endocrinol (Oxf) 1994, 41: 473–81.
Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992, 37: 119–25.
Talbott E, Guzick D, Clerici A, et al. Coronary hearth disease risk factors in women with polycystic ovary syndrome. Arte-rioscler Thromb Vasc Biol 1995, 15: 821–6.
Remsberg KE, Talbott EO, Zborowski JV, Evans RW, McHugh-Pemu K. Evidence for competing effects of body mass, hyper-insulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women with polycystic ovary syndrome. Fertil Steril 2002, 78: 479–86.
Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982, 54: 254–60.
Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994, 17: 961–9.
Huang Z, Willett WC, Manson JE, et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998, 128: 81–8.
Pouliot MC, Despres J P, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthro-pometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994, 73: 460–8.
Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 1017–23.
Douchi T, Yoshimitsu N, Nagata Y. Relationships among serum testosterone levels, body fat and muscle mass distribution in women with polycystic ovary syndrome. Endocr J 2001, 48(6): 685–9.
Paradisi G, Smith L, Burtner C, et al. Dual energy x-ray absorptiometry assessment of fat mass distribution and its association with the insulin resistance syndrome. Diabetes Care 1999, 22: 1310–7.
Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil. Steril. 2003, 79(6): 1358–64.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Faloia, E., Canibus, P., Gatti, C. et al. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest 27, 424–429 (2004). https://doi.org/10.1007/BF03345285
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345285